Chugai Pharmaceutical Co., Ltd. (TYO: 4519)

Chugai Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	982,743	974,493	1,039,247	802,836	633,314	588,896
Other Revenue	159,607	136,874	220,699	196,923	153,632	97,288
Revenue	1,142,350	1,111,367	1,259,946	999,759	786,946	686,184
Revenue Growth (YoY)	-10.48%	-11.79%	26.02%	27.04%	14.68%	18.35%
Cost of Revenue	337,168	413,306	476,251	338,147	273,465	266,071
Gross Profit	805,182	698,061	783,695	661,612	513,481	420,113
Selling, General & Admin	108,439	112,580	100,760	102,416	94,401	101,574
Research & Development	171,068	174,868	149,626	137,299	117,850	107,942
Other Operating Expenses	-14,503	-28,561	-	-	-	-
Operating Expenses	265,004	258,887	250,386	239,715	212,251	209,516
Operating Income	540,178	439,174	533,309	421,897	301,230	210,597
Interest Expense	-8	-27	-61	-48	-62	-125
Interest & Investment Income	-	4,674	52	-	-	545
Other Non Operating Income (Expenses)	47	-	-2,134	-2,464	-2,980	-3,124
EBT Excluding Unusual Items	540,217	443,821	531,166	419,385	298,188	207,893
Pretax Income	540,217	443,821	531,166	419,385	298,188	207,893
Income Tax Expense	153,253	118,349	156,737	116,390	83,455	50,333
Earnings From Continuing Operations	386,964	325,472	374,429	302,995	214,733	157,560
Net Income	386,964	325,472	374,429	302,995	214,733	157,560
Net Income to Common	386,964	325,472	374,429	302,995	214,733	157,560
Net Income Growth	14.91%	-13.08%	23.58%	41.10%	36.29%	70.36%
Shares Outstanding (Basic)	1,645	1,645	1,645	1,644	1,643	1,642
Shares Outstanding (Diluted)	1,646	1,645	1,645	1,645	1,645	1,645
Shares Change (YoY)	0.01%	0.01%	0.01%	0.01%	0.03%	0.05%
EPS (Basic)	235.18	197.83	227.64	184.29	130.66	95.95
EPS (Diluted)	235.15	197.80	227.57	184.17	130.53	95.81
EPS Growth	14.90%	-13.08%	23.57%	41.09%	36.24%	70.28%
Free Cash Flow	351,009	337,977	181,487	213,657	147,995	153,632
Free Cash Flow Per Share	213.30	205.39	110.30	129.86	89.96	93.42
Dividend Per Share	81.000	80.000	78.000	76.000	55.000	32.000
Dividend Growth	102.50%	2.56%	2.63%	38.18%	71.88%	11.63%
Gross Margin	70.48%	62.81%	62.20%	66.18%	65.25%	61.22%
Operating Margin	47.29%	39.52%	42.33%	42.20%	38.28%	30.69%
Profit Margin	33.87%	29.29%	29.72%	30.31%	27.29%	22.96%
Free Cash Flow Margin	30.73%	30.41%	14.40%	21.37%	18.81%	22.39%
EBITDA	567,090	470,914	564,743	452,765	331,606	236,998
EBITDA Margin	49.64%	42.37%	44.82%	45.29%	42.14%	34.54%
D&A For EBITDA	26,912	31,740	31,434	30,868	30,376	26,401
EBIT	540,178	439,174	533,309	421,897	301,230	210,597
EBIT Margin	47.29%	39.52%	42.33%	42.20%	38.28%	30.69%
Effective Tax Rate	28.37%	26.67%	29.51%	27.75%	27.99%	24.21%
Revenue as Reported	1,142,350	-	-	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.